• Regen BioPharma replaced auditor BCRG Group with Simon & Edward LLP on July 13, 2026, following S&E’s June 15 acquisition of BCRG’s attest business.
• BCRG’s audit opinions for fiscal 2025 and 2024 were clean, but included a going-concern paragraph citing substantial doubt about the company’s ability to continue.
• No accounting or auditing disagreements were reported with BCRG; the only cited reportable issue was previously disclosed material weaknesses in internal controls.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regen BioPharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-033364), on July 15, 2026, and is solely responsible for the information contained therein.